NEW YORK, Nov. 5, 2010 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: WDST) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that their November 4th investor presentation is available for archive viewing.
Regenicin's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.
The Regenicin presentation, which was given by CEO, Randall McCoy and CFO, John Weber, provides an overview of Regenicin's role in the development of the product candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. These living self-to-self skin graft tissue are intended to form permanent skin that will grow with the patient and not be rejected by the immune system, a critical possibility in porcine or cadaver skin grafts used today.
Regenicin, Inc., is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New York City.
|SOURCE Regenicin(TM), Inc.|
Copyright©2010 PR Newswire.
All rights reserved